Finasteride Tablet, Film Coated
Product Images NDC 68788-8749

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 68788-8749). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 Symptom Score In A Long-term Efficacy And Safety Study (Finasteride Fig1)

A line graph titled 'Symptom Score in a Long-Term Efficacy and Safety Study' showing mean change from baseline ± 1 SE on the vertical axis over four years on the horizontal axis, comparing Finasteride and placebo groups. Finasteride shows a greater reduction in symptom score over time compared to placebo, with sample sizes noted for each group at baseline and each year.*

FDA Label Image

Figure 2 Percent Of Patients Having Surgery For Bph, Including Turp (Finasteride Fig2)

A line graph showing the percent of patients having surgery for BPH, including TURP, over 48 months. The solid line represents the Finasteride group, and the dashed line represents the placebo group. The graph shows a lower cumulative percent of surgery events in the Finasteride group. Below the graph, tables list cumulative number of events and number of patients at risk per year for both groups.*

FDA Label Image

Figure3 (Finasteride Fig3)

A line graph titled 'Percent of Patients Developing Acute Urinary Retention (Spontaneous and Precipitated)' comparing Finasteride and placebo over a 48-month observation period. The y-axis shows percent of patients (0% to 15%), and the x-axis shows time in months (0 to 48). Finasteride shows a lower cumulative incidence than placebo. Below the graph are tables listing cumulative event counts and number of patients at risk per year for both groups.*

FDA Label Image

Figure4 (Finasteride Fig4)

A line graph titled 'Prostate Volume in a Long-Term Efficacy and Safety Study' showing mean percent change from baseline with standard error bars over a 4-year period. The graph compares two groups: Placebo and Finasteride, with data points at baseline, Year 1, Year 2, Year 3, and Year 4. Placebo shows an increasing prostate volume over time, while Finasteride shows a significant decrease initially that stabilizes through Year 4. Sample sizes at each time point for both groups are indicated below the graph.*

FDA Label Image

Figure5 (Finasteride Fig5)

A line graph titled "Cumulative Incidence of a 4-Point Rise in AUA Symptom Score by Treatment Group" showing percent with event on the Y-axis against years from randomization on the X-axis. The graph compares four treatment groups: Placebo, Finasteride, Doxazosin, and Combination, with distinct markers for each group's cumulative incidence over approximately 5.5 years.*

FDA Label Image

Finasteride Tablets Usp 5mg (Finasteride Fig6)

Finasteride Tablets USP 5 mg film-coated oral tablets packaging label. The label shows the product name and strength prominently on a yellow background, identifies it as generic for Proscar, and lists Aurobindo Pharma Limited as the manufacturer. It includes storage instructions, dosage warnings, and a caution about drug transfer. The label also features the Preferred Pharmaceuticals, Inc. logo and dosage directions in both English and Spanish in a yellow section with a QR code.*

FDA Label Image

Chemical Structure (Finasteride Str)

Chemical structure diagram of Finasteride, showing its steroid-like four-ring core with attached functional groups including an amide and methyl substituents, consistent with the active ingredient Finasteride.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.